Tuesday, January 19, 2010

The Science of Innovation

by Gillian Parrish, Manager, Alliance Development and Communications
Now that the holiday dust (and snow!) has settled, the medical research community is buckling down for a busy and productive year. This past week brought forth a flurry of ideas and activity on everything from:
  • Evaluating the research implications of HHS’s new rule on what constitutes “meaningful use” of health information technology; to
  • Moving the next phase of FDA’s Sentinel Initiative to track product safety forward; to
  • Driving more and better collaboration among patient registries and biobanks.
FasterCures participated in a number of these, including a meeting of the President’s Council of Advisors on Science and Technology (PCAST), the 2nd Annual Sentinel Initiative Public Workshop and The NIH’s Office of Rare Disease Research’s (ORDR) Advancing Rare Disease Research Conference. A common thread we heard across all of the discussions was the need for better communication and collaboration, especially around procedural practices and data.
Atul Gawande refers to this systematic exchange of best practices as “process science.” He describes it as applying the same scientific rigor currently placed on the discovery of new medical solutions to delivery of those solutions. But between discovery and delivery, we believe there is another step that is just as critical to this equation – translation.
Translation, the bridge between basic and clinical research, is a seminal process that drives the engine of delivery, but one in which we often lose the most time and resources. Essentially considered phase two of discovery, it is the application of ideas and insights generated through that rigorous science Dr. Gawande talks about to the treatment and prevention of human disease.
Regardless of how exact and scientific the initial discovery process may be, however, if valuable data sets and research models uncovered though that process aren’t shared and systematized, their translation into solutions that providers can deliver will take years longer than necessary.
The NIH is trying to incentivize more translational research through its Roadmap initiative and specific programs such as the Clinical and Translational Science Awards and the new Therapeutics for Rare and Neglected Diseases (TRND) program. But there remains an enormous amount to be done.
This week, we heard some great ideas for getting those research models and data sets flowing in ways that could considerably reduce the time and improve the standard operating procedures between discovery and delivery. They are:
  • Supporting the exchange of de-identified patient data through electronic health records (EHRs) for research purposes, and ensuring that the final meaningful use rule includes language to that effect
  • Reevaluating the informed consent process to more clearly distinguish between the use of electronic information for public health surveillance versus scientific research
  • Building an empirically evaluated methods library for innovative clinical trial models
  • Developing standards and guidelines for biospecimen collection and management so those processes can be reproduced
  • Identifying and training biospecimen champions at hospitals and health systems where procedures take place -- possibly even establishing a national “concierge resource” for biospecimen collection
  • Connecting biorepositories with robust clinical data sets, such as those available through the National Cancer Institute's cancer Human Biobank (caHUB)
  • Expanding and improving ORDR’s “registry of registries,” building it out with individual researchers across all rare diseases and making it fully query-able
We’ll closely track the progress of these efforts in the coming months and find ways to work with the drivers to see where and how FasterCures can help. The more information we can get flowing between researchers now, the faster we’ll be able to translate those discoveries into solutions that Dr. Gawande and his peers can deliver.

Thursday, January 7, 2010

Read Margaret Anderson's Blog on The Huffington Post



Top 10 Medical Research Trends to Watch in 2010
by Margaret Anderson, Executive Director, FasterCures

This Top-10 list, assembled by Margaret Anderson, Executive Director, FasterCures, reveals some likely medical and scientific trends that will affect research in 2010, including FDA regulation, healthcare, information technology, and new methods in clinical trials and research. Read more.

Wednesday, December 23, 2009

'Tis the season

'Tis the season for digging out from under and clearing off the piles and the clutter. 'Tis the season for looking back at the year that flew and planning ahead for a year that's new.

At FasterCures, we will launch our new strategic plan in the coming months, an effort to help us "stay in our lane" and focus on much needed outcomes towards accelerating medical solutions. As FasterCures board member Larry Flax has said, "That which gets measured gets done."

As we further define our strategic priorities and implement outcomes-driven programs, here’s a preview of what’s on our agenda for 2010:
  • Fostering innovation and accountability in medical research.
  • Creating a more informed, transparent, and results-oriented marketplace for medical philanthropy.
  • Empowering patients to play an active role in clinical research.
  • Exploring and expanding opportunities at the Food and Drug Administration for acceleration of cures.
  • Strengthening medical research tools (e.g., electronic health records, biobanks) to better support a more effective and efficient health cures system.
We look forward to hearing from you in the new year, and working with you to advance our mission of saving lives by saving time. Wishing everyone health and a multitude of outcomes that advance cures in the new year.

Wednesday, December 16, 2009

Putting Cures on the Health Reform Agenda

by Margaret Anderson, Executive Director, FasterCures

For months, we've all heard arguments from all sides about how best to improve our health care system. Many of the solutions that have surfaced have focused on curbing costs and improving quality of care - unarguably critical issues that need to be addressed. As the marathon search for solutions is approaching sprint speed, we at FasterCures wanted to share that the search for cures has made it on the agenda. Senator Arlen Specter (D-PA) introduced the Cures Acceleration Network (CAN) Act of 2009 as an amendment (SA 2866) to the health reform bill in the Senate.

The Specter amendment seeks to expedite the time it takes to turn a scientific discovery into an accessible, life-saving therapy by establishing CAN within the Office of the Director of the National Institutes of Health. Among the functions of the CAN are to:
  • conduct and support revolutionary advances in basic research, translating scientific discoveries from bench to bedside;
  • award grants and contracts to eligible entities to accelerate the development of high need cures;
  • provide the resources necessary for government agencies, independent investigators, research organizations, biotechnology companies, academic research institutions, and other entities to develop high need cures;
  • reduce the barriers between laboratory discoveries and clinical trials for new therapies; and
  • facilitate review in the Food and Drug Administration for the high need cures funded by the CAN.
We need to do a better job of translating promising scientific research into new means of preventing and treating disease. Otherwise, we will not be able to contain health care costs, improve productivity and prevent human suffering. Unless we invest in an effective medical research enterprise as part of an effort to improve our health system, we are limiting ourselves to stop-gap measures that will be unsustainable in the long-term.

For all the human and financial capital flowing through our healthcare system, there remains a formidable list of diseases for which there are no cures or even meaningful treatment options. And yet, it can take nearly two decades to turn a research discovery into a medical solution. Our need for cures has never been greater.

Tuesday, December 15, 2009

FasterCures Names Margaret Anderson Executive Director

WASHINGTON (December 15, 2009) – FasterCures, an organization committed to saving lives by saving time in the research, discovery and development of new medical solutions, today announced the appointment of Margaret Anderson as its Executive Director. Anderson will lead the organization, defining its strategic priorities and positions on key issues, developing its programmatic portfolio, and managing its operations.

Prior to her appointment as Executive Director, Anderson was FasterCures’ COO for five years. Since its inception in 2003, FasterCures, the Washington-based center of the Milken Institute, has worked independently and with partners to break down the barriers that exist across the research continuum—from basic research to drug development—to clear the path to faster medical progress. These include the following programs: the Philanthropy Advisory Service, an online information marketplace designed to make philanthropic investment in medical research more effective and productive; “TRAIN” (The Redstone Acceleration and Innovation Network), established to create opportunities for medical research innovators to discuss and tackle the challenges that cut across diseases; and PHD (Patients Helping Doctors), an effort aimed to empower patients to contribute to medical research.

“Margaret has been a steady and inspirational leadership force at FasterCures for years," said Michael Klowden, President and CEO of the Milken Institute. "She's been instrumental in developing and implementing strategies that set the organization apart. And she has the unique combination of knowledge, leadership abilities and enthusiasm it takes to energize the biomedical research community.

"The FasterCures mission is to facilitate a medical research culture that encourages innovation and collaboration, operates efficiently and transparently, and - most importantly - gets results. Margaret has proven herself to be the right person to get this done in her new leadership position," added Klowden.

Most recently, FasterCures convened the inaugural Partnering for Cures meeting in New York City, the first‐of‐its‐kind effort that brought together philanthropy, medical research foundations, and the biotechnology and pharmaceutical industries in an effort to forge strategic collaborations needed to expedite the search for cures.